



Comparative study of the effect of Rantidine and Pantoprazole on Incidence of Ventilator-Associated Pneumonia

Thesis

Submitted for the Partial Fulfillment of Master Degree
in General Intensive Care

By

Eslam Saad Mohamed Ali Elfeky

M.B.B.,Ch -
Alexandria University

Under Supervision of

Prof. Dr. Sherif Farouk Ibrahim

Professor of Anesthesia and Intensive Care
Faculty of Medicine–Ain Shams University

Ass. Prof. Dr. Niven Girgis Fahmy

Assistant Professor of Anesthesia and Intensive Care
Faculty of Medicine–Ain Shams University

Dr. Tarek Samir Shabana

Lecturer in of Anesthesia and Intensive Care
Faculty of Medicine–Ain Shams University

**Faculty of Medicine
Ain Shams University
2018**



ACKNOWLEDGEMENT

First of all, thanks to **Allah** whose magnificent help was the main factor in completing this work.

I'm greatly indebted to **Prof. Dr. Sherif Farouk Ibrahim**, Professor of Anesthesia and Intensive Care, Ain Shams Faculty of medicine for his kind help and guidance throughout the whole work.

I wish to express my deepest gratitude and sincere appreciation to **Ass. Prof. Dr. Niven Girgis Fahmy**, Assistant Professor of Anesthesia and Intensive Care, Ain Shams Faculty of Medicine, for her close supervision, encouragement and assistance.

Also I wish to express my deepest gratitude and sincere appreciation to **Dr. Tarek Samir Shabana**, Lecturer in of Anesthesia and Intensive Care, Ain Shams University Maternity Hospital, for his close supervision, encouragement and assistance.

Hamda Abdelhamid Omar Mohamed

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العليم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Contents

Subjects	Page
List of abbreviations.....	II
List of figures.....	IV
List of tables.....	V
• Introduction	1
• Aim of the Work	5
• Review of Literature	6
• Patients and Methods	43
• Results	47
• Discussion	65
• Summary and Conclusion	74
• References	78
• Arabic Summary	

List of Abbreviations

ARDS	: Acute respiratory distress syndrome
ATS	: American Thoracic Society
ATS	: American Thoracic Society
BAL	: Bronchoalveolar lavage
CNS	: Coagulase-negative staphylococcus
CPIS	: Clinical pulmonary infection score
ESBL	: Extended-spectrum beta-lactamase producing bacteria
ETT	: Endotracheal tube
GERD	: Gastroesophageal Reflux Disease
GI	: Gastrointestinal
H2	: Histamine type 2
H2RAs	: Histamine2 receptors antagonists
HAIs	: Hospital acquired infections
HAP	: Hospital-acquired pneumonia
ICU	: Intensive care units
IDSA	: Infectious Diseases Society of America
IVAC	: Infection- related ventilator-associated complications

List of Abbreviations

MDR	: Multidrug resistant
MSSA	: Methicillin-sensitive <i>Staphylococcus aureus</i>
OGD	: Oesophagogastroduodenoscopy
PPIs	: Proton pump inhibitors
PSB	: Protected specimen brush
RRT	: Renal replacement therapy
SRMD	: Stress-related mucosal damage'
SUP	: Stress ulcer prophylaxis
VAP	: Ventilator-associated pneumonia

List of Figures

<u>No.</u>	<u>Figure</u>	<u>Page</u>
<u>1</u>	Demographic data of the studied groups.	47
<u>2</u>	Comparison between two groups according to APACHE II and SOFA score.	50
<u>3</u>	Comparison between the two studied groups regarding blood picture level.	52
<u>4</u>	Comparison between the two studied groups regarding vital signs level at different period of follow up.	55
<u>5</u>	Comparison between the two studied groups regarding blood cultures during hospital stay.	57
<u>6</u>	Comparison between the two studied groups regarding sputum cultures during hospital stay.	59
<u>7</u>	Comparison between the two studied groups regarding VAP incidence.	60
<u>8</u>	Comparison between the two studied groups regarding onset of VAP (days).	61
<u>9</u>	Comparison between the two studied groups regarding hospital Stay (days).	62
<u>10</u>	Comparison between the two studied groups regarding duration of intubation.	63
<u>11</u>	Comparison between the two studied groups regarding hospital mortality.	63

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>1</u>	Risk factors for the development of ventilator associated pneumonia.	8
<u>2</u>	The clinical pulmonary infections core.	14
<u>3</u>	Suggested Empiric Treatment Options for Clinically Suspected Ventilator-Associated Pneumonia.	24
<u>4</u>	Demographic data of the studied groups	47
<u>5</u>	Comparison between two groups according to APACH II and SOFA score.	49
<u>6</u>	Comparison between the two studied groups regarding blood picture levels.	51
<u>7</u>	Comparison between the two studied groups regarding vital signs level at different period of follow up.	54
<u>8</u>	Comparison between the two studied groups regarding blood cultures during hospital stay.	56
<u>9</u>	Comparison between the two studied groups regarding sputum cultures during hospital stay.	58
<u>10</u>	Comparison between the two studied groups regarding VAP incidence.	60
<u>11</u>	Comparison between the two studied groups regarding onset of VAP (days).	61

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>12</u>	Comparison between the two studied groups regarding hospital Stay (days).	62
<u>13</u>	Comparison between the two studied groups regarding duration of intubation.	63
<u>14</u>	Comparison between the two studied groups regarding hospital mortality.	64

Introduction

Nosocomial pneumonia is the leading infectious cause of death in critically ill patients **(Porzecanski et al., 2006)**.

The crude mortality rate is estimated to be 20 to 50%, with an average increase in hospital stay of 7 to 9 days **(Tablan et al., 2003)**.

Ventilator-associated pneumonia (VAP) is defined as a group of pneumonias that occur 48 h after the patient is ventilated if the patient did not have primary signs of the infection at the time of arriving ICU. VAP is one of the most prevalent nosocomial infections and pneumonia is the cause of 27% of infections in ICU **(Zandyeh et al., 2005)**.

In healthy individuals multiple mechanisms work together to fight off the development of pneumonia; the presence of an ETT as well as the typical clinical circumstances of ICU patients (i.e. sedation, supine positioning colonization of the oropharynx with pathogenic microorganisms) interfere with these native defense

mechanisms and predispose intubated patients to the development of VAP (**Keyt et al., 2014**).

Symptoms and signs of pneumonia are fever, leukocytosis and purulent discharge. Laboratory testing is the best diagnostic method. Administration of antibiotics and cooperation with laboratory are important subjects after diagnosis. Furthermore, as the duration of hospitalization increases, the risk of VAP and incidence of more dangerous organisms in ventilated patients increase (**Zandyeh et al., 2005**).

Some studies have reported that the incidence of nosocomial pneumonia increases by 30% following pharmacological stress ulcer prophylaxis. Acid-suppressive medications such as proton pump inhibitors and histamine type 2 (H2) receptor antagonists are used to prevent stress ulcers. Theoretically, the inhibition of gastric acid secretion can be associated with increased gastric colonization as well as retrograde colonization of the pharynx leading to VAP with potential micro-aspiration (**Herzig et al., 2009**).

Pneumonia has also been associated with patient exposure to PPI therapy; Salivary gland secretions, gastric acid and well synchronized gastric motility are innate

mechanisms to restrict bacterial colonization in the gastric lumen. A gastric pH of less than 2 effectively limits bacterial colonization from ingested microbes. Since PPIs effectively increase the gastric pH above 4 for the majority of a 24-h period, this defense mechanism against the colonization of ingested bacteria is compromised. Consequently, due to the reduced gastric acidity, the bacterial load increases in the stomach (**Savarino et al., 2009**).

Single or repeated administration of PPIs may in fact lead to delayed gastric emptying, increased gastric contents, increased bacterial load and increased pressure on the lower esophageal sphincter that lead to retrograde movement of gastric contents up the esophagus. This reflux may then increase the risk of subsequent aspiration of both the gastric contents and the bacteria (**Savarino et al., 2009**).

In randomized Double-Blind Clinical Trial comparing the effect of ranitidine and pantoprazole and reporting the incidence of VAP to be three times higher in patients receiving pantoprazole (**Rahimi et al., 2013**).

Thus, our study designed to determine whether prophylaxis with the PPI pantoprazole increases the risk of nosocomial pneumonia compared with prophylaxis with the H2RA ranitidine in mechanically ventilated patients.

Aim of the Work

The aim of this work is to compare the effects of ranitidine and pantoprazole on incidence of Ventilator Associated Pneumonia (VAP).

Review of Literature

Hospital-acquired (or nosocomial) pneumonia (HAP) is pneumonia that occurs 48 hours or more after admission and did not appear to be incubating at the time of admission **(Kalil et al., 2016)**.

Ventilator associated pneumonia (VAP), a subset of HAP, is defined as pneumonia that occurs 48 - 72 hours following endotracheal intubation. It is characterized by the presence of new or progressive pulmonary infiltrates, signs of systemic infection (as fever or altered white blood cell count), changes in sputum characteristics, and detection of a causative agent **(Kalil et al., 2016)**.

Ventilator associated pneumonia is the second most common nosocomial infection in the intensive care unit and the most common in mechanically ventilated patients **(Hunter, 2012)**.

Together, HAP and VAP are among the most common hospital acquired infections (HAIs), accounting for 22% of all hospital acquired infections (HAIs) in a multistate point-prevalence survey **(Magill et al., 2014)**.